Knome, a US-based life sciences company specialising in genome research, appointed Martin Tolar as its chief executive officer on Monday. Tolar previously held the same position at biopharmaceutical company Normoxys.

Prior to helming Normoxys, Tolar held executive positions at pharmaceutical companies CoMentis and Pfizer, where he played a significant role in the corporation’s acquisition of Rinat Neurosciences in 2006.

Founded in 2007, Knome works on interpreting human genomes likely to govern particular diseases and responses to drug treatments. Academic, pharmaceutical…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?